Valitor's VLTR-559 Shows Extended Six-Month Durability in Wet AMD Preclinical Studies
核心洞察
Valitor (搜索) presented preclinical data at ARVO 2026 demonstrating VLTR-559 (搜索)'s superior durability with a 12-day vitreous half-life compared to 3-5 days for conventional anti-VEGF (搜索) biologics.
The long-acting anti-VEGF (搜索) therapy maintained unchanged potency for up to 76 days and showed favorable safety without elevated intraocular pressure or aqueous flares.
VLTR-559 (搜索) remained in ocular tissues three to four times longer than first-generation anti-VEGFs, potentially enabling twice-yearly dosing for wet age-related macular degeneration treatment.
Valitor (搜索) announced compelling preclinical data for VLTR-559 (搜索), a long-acting anti-VEGF (搜索) biologic designed to transform wet age-related macular degeneration (AMD) treatment through twice-yearly dosing. The data, presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, demonstrated superior durability, sustained anti-VEGF activity, and favorable safety profile compared to conventional treatments.
Extended Durability Profile
In preclinical models, VLTR-559 (搜索) demonstrated a substantially longer vitreous half-life of 12 days compared to conventional anti-VEGF (搜索) biologics, which have a half-life of 3-5 days. The therapy was detected in the retina and retinal pigment epithelium (RPE)/choroid tissues at high concentrations, demonstrating its ability to persist in vitreous tissue.
The anti-VEGF (搜索) potency of VLTR-559 (搜索) remained unchanged for the study duration of up to 76 days following administration, reinforcing its stability in ocular tissues. Data showed that VLTR-559 remained in ocular tissues including the retina three to four times longer than first-generation anti-VEGFs, demonstrating unprecedented durability at the target site without losing potency.
Safety and Tolerability
VLTR-559 (搜索) was well-tolerated without elevated intraocular pressure and without any aqueous flares. The preclinical studies showed that VLTR-559 exhibited safety and efficacy consistent with approved short-acting anti-VEGF (搜索) therapies. These results indicate VLTR-559 has superior durability compared to approved anti-VEGF treatments and is on track to enable a reliable and well-tolerated 6-month treatment protocol for patients with wet AMD.
Addressing Treatment Burden
Anti-VEGF (搜索) therapy represents the gold-standard treatment for wet AMD; however, current generation anti-VEGFs require a high burden of intravitreal injections and frequent office visits for disease monitoring to prevent losses in efficacy over the long-term. The majority of patients currently require dosing approximately every 8-12 weeks with market leaders.
"We continue to be encouraged by the superior durability, efficacy and safety profile of VLTR-559 (搜索) observed in preclinical models for the treatment of wet AMD," said Gregory D. Kunst, chief executive officer of Valitor (搜索). "These latest data presented at the ARVO annual meeting further reinforce the potential of VLTR-559 to transform the treatment landscape of wet-AMD, as a single dose to induce and sustain efficacy for more than six-months and meaningfully reduce the treatment burden for patients."
Multivalent Polymer Technology
VLTR-559 (搜索) was developed using Valitor (搜索)'s proprietary multivalent polymer (MVP) technology platform to enable reliable dosing only twice yearly, with the overall goal of improving long-term efficacy. The MVP platform is based on proprietary multivalent biopolymers coupled with bioactive molecules, allowing for independent control of multiple drug attributes including pharmacokinetic/pharmacodynamic properties, improved target engagement/tissue localization, therapeutic durability, and improved safety.
In research studies, Valitor (搜索)'s novel compounds have shown 10-fold increases in potency, up to 5-fold increases in tissue retention, and excellent preclinical safety.
Clinical Development Timeline
Valitor (搜索) is advancing VLTR-559 (搜索) through IND-enabling activities and plans to advance the therapy into clinical evaluation next year. The company is initially focused on developing long-acting molecules aimed at capturing several large markets in ophthalmology, with VLTR-559 as its lead product designed to reliably extend the duration of a single dose in humans to six months or more.